Healwell AI Faces a Defining Quarter as Software Pivot Gathers Pace

Healwell AI reports Q1 results May 7 amid clinical sale finalization and Amadeus AI platform launch. Stock near 52-week low with oversold RSI, but revenue surged 427% in FY2025.

The next few weeks will be pivotal for Healwell AI. The Canadian healthcare technology company is due to report its fiscal first-quarter results on May 7, just as it races to finalize the sale of its clinical operations and launch a unified artificial intelligence platform that management hopes will reshape its fortunes.

Investors have been cautious. The stock, trading at around C$0.59, sits roughly 43% below its 52-week high. Technical indicators, including a relative strength index near 30, point to oversold conditions, but the market’s wariness runs deeper than price action alone.

A Clean Break from Clinical Operations

Healwell is in the final stages of shedding its remaining clinical business. In late March, the company signed a letter of intent to sell HEAL Access Canada to AI Maverick Intel in exchange for 20 million exchangeable shares. A binding agreement is expected by May 29, marking the last major step in a transition toward a pure-play subscription-based software model.

The divestiture strategy is not new. During the fourth quarter of 2025, similar sales generated roughly C$9.7 million in cash. The company has been methodically pruning everything outside its core artificial intelligence software focus.

The Numbers Tell a Story of Transformation

Healwell’s full-year 2025 results already hinted at the scale of the shift. Revenue from continuing operations surged to C$103.8 million, a 427% jump from the prior year, driven largely by the acquisition of Orion Health, which closed on April 1, 2025. The company also posted its first full-year positive adjusted EBITDA of C$2.3 million.

But the headline figures mask underlying strain. The IFRS net loss stood at C$46.1 million, and the company continues to burn cash. Research and development consumes roughly 14% of revenue, and with a workforce of 3,500 employees, short-term profitability remains elusive. The gross margin of 45% provides a solid operational base, but the path to sustained profitability is still under construction.

Amadeus AI: The Big Bet

The centerpiece of Healwell’s growth narrative is the launch of Amadeus AI, a unified platform that combines its Khure and Pentavere systems on a single DARWEN™ engine. The company plans to roll out the platform across North America in the first half of 2026, with international expansion slated for the second half.

Stifel analyst Justin Keywood values Healwell at 2.4 times revenue, below the 2.8 times average for comparable life sciences technology companies. He expects the company to reach free cash flow breakeven by the fourth quarter of 2026, assuming organic contract wins and monetization of its xAI partnership proceed as planned.

Management has set ambitious targets for fiscal 2026: roughly 50% organic growth in AI revenue and an adjusted EBITDA margin of around 10%. The first-quarter results will provide the first measurable data point against those goals.

What to Watch on May 7

The company has already cautioned that the first quarter is likely to be the weakest of the year due to seasonal demand patterns. Investors will be watching closely to see whether Healwell can extend its streak of positive adjusted EBITDA quarters while demonstrating tangible progress on the Amadeus AI rollout.

A conference call with management is scheduled for May 8 at 2:30 p.m. CET. The annual general meeting follows on June 25, with a record date of May 15 for voting shareholders. At that meeting, the board is expected to discuss expansion in the Middle East and progress with North American enterprise customers.

Scientific Credentials and Market Position

Healwell’s scientific foundation continues to deepen. The DARWEN platform has now been referenced in 47 peer-reviewed publications, the most recent appearing in the Journal of Crohn's and Colitis. The company has also secured a multi-year software contract in the U.S. health data network market.

Yet the market capitalization stood at roughly C$266 million at the end of April, about 22% lower than a year ago. Bridging that gap will require the May 7 report to show that the transformation is not just a story of asset sales and cost cutting, but one of genuine revenue momentum from the software business that Healwell has bet its future on.